



Hepatitis C Enrollment Form

Specialty Pharmacy Enrollment Form

Please detach before submitting to a pharmacy – tear here.

PATIENT INFORMATION

Please complete the following or send patient demographic sheet

Patient Name _____

DOB _____ Last Four of SS# _____ Gender _____

Weight _____ Height _____ Phone _____

Address _____

City, State, ZIP _____

Language Preference: English Spanish Other _____

PRESCRIBER INFORMATION

Prescriber's Name _____

DEA _____ NPI _____

Group/Hospital _____

Address _____

City, State, ZIP _____

Phone _____ Fax _____

Contact Person _____ Phone _____

INSURANCE INFORMATION (Must fax a copy of patient's insurance card including both sides)

Prior Authorization Reference number _____

MEDICAL INFORMATION (Section must be completed to process prescription) (Attach separate sheet if needed)

B18.2 Chronic Hepatitis C K72.90 Hepatic failure, unspecified without coma C22.0 Liver Cell Carcinoma

Other Diagnosis: ICD-10 Code _____ Description _____

Genotype _____ Viral Load _____ IU/ml Viral Load Date _____ HIV Coinfected: Yes No HBV Coinfected: Yes No

Previous therapy history: Naïve _____ Relapsed _____ Partial Responder _____ Null _____

Date(s) of previous therapy and meds _____

Cirrhosis: Yes No Compensated OR Decompensated Fibrosis Score _____

Liver Transplant: Yes No Waiting for Liver Transplant: Yes No

Please include hard copies of: genotype, viral load, liver biopsy scans, CBC, CMP, HIV, PT/INR, H&P, NS5A resistance testing and pertinent office visit notes.

PRESCRIPTION INFORMATION

EPCLUSA (sofosbuvir 400mg/velpatasvir 100mg) disp. 28 Sig: 1 tablet daily Refill: x _____ Total duration of therapy _____ Weeks

HARVONI® (ledipasvir 90mg/sofosbuvir 400mg) disp. 28 Sig: 1 tablet daily Refill: x _____ Total duration of therapy _____ Weeks

MAVYRET™ (glecaprevir 100mg/pibrentasvir 40mg) disp 84 Refill: x _____ Total duration of therapy _____ Weeks
Sig: Take 3 tablets (contents of one daily dose card) by mouth once daily with food.

RIBAVIRIN 200mg:

Directions _____

Quantity _____

Refill: x _____ Total duration of therapy _____ Weeks

< 75kg = 1000mg/day

≥ 75kg = 1200mg/day

RIBAPAK (28 day supply):

1200mg daily/600mg QAM—600mg QPM

1000mg daily/600mg QAM—400mg QPM

800mg daily/400mg QAM—400mg QPM

600mg daily/200mg QAM—400mg QPM

Refill: x _____ Total duration of therapy _____ Weeks

MODERIBA (28 day supply):

1200mg daily/600mg QAM—600mg QPM

1000mg daily/600mg QAM—400mg QPM

800mg daily/400mg QAM—400mg QPM

600mg daily/200mg QAM—400mg QPM

Refill: x _____ Total duration of therapy _____ Weeks

SOVALDI™ (sofosbuvir) 400mg disp. 28 Sig: 400mg daily Refill: x _____ Total duration of therapy _____ Weeks

VOSEVI Disp. 28 day supply Sig: Take once daily with food Refill: x _____ Total duration of therapy _____ Weeks

ZEPATIER (elbasvir 50mg/grazoprevir 100mg) disp. 28 Refill: x _____ duration of therapy _____ Weeks
Sig: Take 1 tablet daily with or without food. NS5A resistance testing included

Supportive Therapy: **PROMACTA**® PO QD 12.5mg tablets 25mg tablets 50mg tablets 75mg tablets 100mg tablets

Quantity _____ Refill: x _____ Total duration of therapy _____ Weeks ***Titrate based on platelet count not to exceed 100mg PO QD**

***Prescriber Authorization:** I authorize this pharmacy and its representatives to act as my authorized agent to secure coverage and initiate the insurance prior authorization process for my patient(s), and to sign any necessary forms on my behalf as my authorized agent, including the receipt of any required prior authorization forms and the receipt and submission of patient lab values and other patient data. In the event that this pharmacy determines that it is unable to fulfill this prescription, I further authorize this pharmacy to forward this information and any related materials related to coverage of the product to another pharmacy of the patient's choice or in the patient's insurer's provider network.

Ship to: Patient Office First Fill (future fills to Patient) Office ALL fills Other _____ Date _____ Needs by Date _____

Product Substitution permitted Dispense as Written

Prescriber's Signature _____ Date _____ Supervising Physician Signature _____ Date _____

Electronic or digital signatures not accepted.

CONFIDENTIALITY STATEMENT: This communication is intended for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law. If the reader of this communication is not the intended recipient or the employee or agent responsible for delivery of the communication, you are hereby notified that any dissemination, distribution, or copying of the communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone.